



- (51) **International Patent Classification:**
C07D 309/28 (2006.01)
- (21) **International Application Number:**
PCT/US2024/041658
- (22) **International Filing Date:**
09 August 2024 (09.08.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/518,854 10 August 2023 (10.08.2023) US
- (71) **Applicant: BIOHAVEN THERAPEUTICS LTD.**
[US/GB]; Biohaven Therapeutics Ltd., Ritter House, P.O. Box 173, Road Town, Tortola, VG1110 (VG).
- (72) **Inventors: LEAHY, David;** c/o Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US). **BODUGAM, Mahipal;** c/o Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US). **ANUSUYA, Bal Reddy;** c/o Biohaven Therapeutics Ltd., 215 Church Street, New Haven, Connecticut 06510 (US).
- (74) **Agent: SABATELLI, Anthony D.;** Wiggins and Dana LLP, 265 Church Street, New Haven, Connecticut 06510 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,

(54) **Title:** PROCESS FOR PRODUCING (3S,6R)-6-(CYANOMETHYL)-TETRAHYDRO-2H-PYRAN-3-AMINE




FIG. 3

(57) **Abstract:** The present disclosure relates to processes to synthesize ((3S,6R)-6-(cyanomethyl)-tetrahydro-2H-pyran-3-amine) hydrochloride, a critical drug intermediate. The processes achieve approximately twice the yield percentage of known processes with greener chemistry, and advantageously eliminate resource-intensive steps for improved industrial efficiency and applicability.

[Continued on next page]

LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished
upon receipt of that report (Rule 48.2(g))*